vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and ECB Bancorp, Inc. (ECBK). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $9.5M, roughly 1.7× ECB Bancorp, Inc.). ECB Bancorp, Inc. runs the higher net margin — 27.3% vs -7.8%, a 35.1% gap on every dollar of revenue. On growth, ECB Bancorp, Inc. posted the faster year-over-year revenue change (33.8% vs 27.3%). Over the past eight quarters, ECB Bancorp, Inc.'s revenue compounded faster (23.8% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
DERM vs ECBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $9.5M |
| Net Profit | $-1.2M | $2.6M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 36.7% |
| Net Margin | -7.8% | 27.3% |
| Revenue YoY | 27.3% | 33.8% |
| Net Profit YoY | -182.0% | 79.5% |
| EPS (diluted) | $-0.04 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $9.5M | ||
| Q3 25 | $17.0M | $8.8M | ||
| Q2 25 | $15.0M | $8.0M | ||
| Q1 25 | $13.1M | $6.9M | ||
| Q4 24 | $12.6M | $7.1M | ||
| Q3 24 | $14.6M | $6.6M | ||
| Q2 24 | $14.9M | $6.3M | ||
| Q1 24 | $13.0M | $6.2M |
| Q4 25 | $-1.2M | $2.6M | ||
| Q3 25 | $-2.3M | $2.4M | ||
| Q2 25 | $-3.8M | $1.4M | ||
| Q1 25 | $-4.1M | $1.3M | ||
| Q4 24 | $1.5M | $1.4M | ||
| Q3 24 | $-2.4M | $1.1M | ||
| Q2 24 | $-3.4M | $791.0K | ||
| Q1 24 | $-10.4M | $621.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 36.7% | ||
| Q3 25 | -9.0% | 37.0% | ||
| Q2 25 | -19.2% | 23.9% | ||
| Q1 25 | -25.3% | 24.9% | ||
| Q4 24 | 17.7% | 27.3% | ||
| Q3 24 | -19.8% | 23.3% | ||
| Q2 24 | -19.7% | 16.9% | ||
| Q1 24 | -77.4% | 13.4% |
| Q4 25 | -7.8% | 27.3% | ||
| Q3 25 | -13.6% | 27.7% | ||
| Q2 25 | -25.3% | 18.0% | ||
| Q1 25 | -31.0% | 18.7% | ||
| Q4 24 | 12.1% | 20.3% | ||
| Q3 24 | -16.3% | 17.2% | ||
| Q2 24 | -22.6% | 12.6% | ||
| Q1 24 | -80.1% | 10.0% |
| Q4 25 | $-0.04 | $0.32 | ||
| Q3 25 | $-0.09 | $0.29 | ||
| Q2 25 | $-0.16 | $0.17 | ||
| Q1 25 | $-0.18 | $0.16 | ||
| Q4 24 | $0.10 | $0.18 | ||
| Q3 24 | $-0.12 | $0.14 | ||
| Q2 24 | $-0.17 | $0.09 | ||
| Q1 24 | $-0.53 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $82.8M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $171.9M |
| Total Assets | $94.6M | $1.6B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $82.8M | ||
| Q3 25 | $24.9M | $201.9M | ||
| Q2 25 | $20.3M | $191.0M | ||
| Q1 25 | $21.1M | $143.7M | ||
| Q4 24 | $20.3M | $309.4M | ||
| Q3 24 | $22.5M | $114.8M | ||
| Q2 24 | $23.9M | $108.7M | ||
| Q1 24 | $24.1M | $109.8M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $171.9M | ||
| Q3 25 | $25.9M | $169.3M | ||
| Q2 25 | $19.2M | $168.3M | ||
| Q1 25 | $21.5M | $168.6M | ||
| Q4 24 | $20.1M | $168.3M | ||
| Q3 24 | $10.9M | $166.0M | ||
| Q2 24 | $11.3M | $166.5M | ||
| Q1 24 | $13.0M | $165.8M |
| Q4 25 | $94.6M | $1.6B | ||
| Q3 25 | $85.2M | $1.6B | ||
| Q2 25 | $81.2M | $1.5B | ||
| Q1 25 | $85.0M | $1.5B | ||
| Q4 24 | $80.2M | $1.4B | ||
| Q3 24 | $64.0M | $1.4B | ||
| Q2 24 | $65.2M | $1.3B | ||
| Q1 24 | $66.6M | $1.3B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $9.2M |
| Free Cash FlowOCF − Capex | — | $9.0M |
| FCF MarginFCF / Revenue | — | 94.7% |
| Capex IntensityCapex / Revenue | — | 2.2% |
| Cash ConversionOCF / Net Profit | — | 3.55× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $9.2M | ||
| Q3 25 | $-2.4M | $4.0M | ||
| Q2 25 | $-942.0K | $1.9M | ||
| Q1 25 | $-2.8M | $-631.0K | ||
| Q4 24 | $2.2M | $6.2M | ||
| Q3 24 | $-1.2M | $861.0K | ||
| Q2 24 | $-5.2M | $1.4M | ||
| Q1 24 | $-5.0M | $-429.0K |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-649.0K | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $-449.0K |
| Q4 25 | — | 94.7% | ||
| Q3 25 | — | 44.9% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | -9.4% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 21.4% | ||
| Q1 24 | — | -7.2% |
| Q4 25 | — | 2.2% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.6% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | 3.55× | ||
| Q3 25 | — | 1.65× | ||
| Q2 25 | — | 1.32× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | 1.46× | 4.31× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | -0.69× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
ECBK
Segment breakdown not available.
